CYTK vs ARWR
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
CYTK · Cytokinetics$53.69 ▼ 3.35%
ARWR · Arrowhead Pharmaceuticals$58.16 ▲ 1.22%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- CYTK -13.7%
- ARWR +45.9%
Head to head
| Metric | CYTK | ARWR |
|---|---|---|
| Price | $53.69 | $58.16 |
| Change today | ▼ 3.35% | ▲ 1.22% |
| Market cap | $7.48B | $8.22B |
| Return, 3 months | -30.7% | -34.2% |
| Return, year to date | -15.5% | -12.4% |
| Return, 1 year | -10.8% | +48.3% |
| P/E (TTM) | – | – |
| P/B | -23.3 | 17.6 |
| P/E percentile vs own 5y | 72nd | 31st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -57.1% | +171.0% |
| Net profit growth (YoY) | -47.9% | -0.1% |
| Gross margin | 80.5% | – |
| Operating margin | -1,046.1% | -33.8% |
| Net margin | -1,321.1% | -47.8% |
| Return on equity | – | -64.8% |
| Analyst target vs. price | +101.6% | +87.4% |
| Analyst buy share | 93% | 92% |
| RSI (14) | 27 | 40 |
| 30-day volatility | 48.8% | 37.2% |
| Max drawdown, 1 year | -38.5% | -37.6% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ARWR is the largest of the group by market value.
- ARWR has returned the most over the past year.
- ARWR is growing revenue fastest.
- ARWR keeps the most profit per dollar of sales.
- ARWR has been the calmest stock over the last 30 days.